AM
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation : a case report | Frontiers in immunology | 2024 | 13 | 13 | |||
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort : a prospective observational cohort study | The lancet. HIV | 2024 | 15 | 0 | |||
Mise à jour du calendrier vaccinal après allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) | Bulletin du cancer | 2024 | 18 | 0 | |||
Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis | Transplant infectious disease | 2024 | 7 | 10 | |||
NK and T cell repertoire is established early after allogeneic HSCT and is profoundly imprinted by CMV reactivation | Blood advances | 2024 | 32 | 25 | |||
Routine infectious disease consultation prior to an allogeneic hematopoietic cell transplant | Open forum infectious diseases | 2023 | 22 | 12 | |||
Myositis manifesting as respiratory insufficiency with anti-RNA polymerase III antibodies : an unusual presentation of graft-versus-host disease | Leukemia and lymphoma | 2023 | 27 | 1 | |||
Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients | Clinical infectious diseases | 2023 | 53 | 19 | |||
Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption | Frontiers in oncology | 2023 | 25 | 9 | |||
CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients | Open forum infectious diseases | 2023 | 59 | 10 | |||
CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation | Leukemia & lymphoma | 2023 | 24 | 12 | |||
Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients | Antimicrobial agents and chemotherapy | 2023 | 52 | 74 | |||
Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant | Open forum infectious diseases | 2023 | 24 | 16 | |||
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | 2023 | 46 | 18 | |||
Modalités et impact de la cryopréservation des greffons allogéniques en contexte pandémique : recommandations de la SFGM-TC | Bulletin du cancer | 2023 | 27 | 0 | |||
Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? | Open forum infectious diseases | 2022 | 221 | 110 | |||
Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation | Frontiers in immunology | 2022 | 57 | 22 | |||
Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections | Mycoses | 2022 | 220 | 101 | |||
Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation : A Retrospective Study | Transplantation and cellular therapy | 2022 | 80 | 37 | |||
T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients | Annals of oncology | 2022 | 111 | 30 | |||
When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients? | Mycoses | 2022 | 58 | 15 | |||
Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation | Blood advances | 2021 | 238 | 77 | |||
The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft | Bone marrow transplantation | 2021 | 254 | 0 | |||
Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients | Bone marrow transplantation | 2021 | 213 | 2 | |||
Suivi au moyen-terme des patients faisant l’objet d’un traitement par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) | Bulletin du cancer | 2021 | 160 | 0 | |||
Real-life considerations on antifungal treatment combinations for the management of invasive mold infections after allogeneic cell transplantation | Journal of Fungi | 2021 | 139 | 81 | |||
Successful treatment of central nervous system lymphoproliferative disorder in a kidney-pancreas and stem cell transplanted patient using intrathecal rituximab | BMJ case reports | 2021 | 175 | 1 | |||
Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation | Leukemia | 2020 | 329 | 235 | |||
Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia | Bone Marrow Transplantation | 2020 | 115 | 0 | |||
Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) | Journal of Hematology & Oncology | 2020 | 183 | 99 | |||
Prérequis pour une production académique des cellules CART conforme aux bonnes pratiques pharmaceutiques (BPF). Recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) | Bulletin du cancer | 2020 | 167 | 66 | |||
Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts | Biology of Blood and Marrow Transplantation | 2020 | 254 | 167 | |||
Procédé de préparation, contrôles de qualité et spécifications des immunosélections CD34+ : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) | Bulletin du cancer | 2020 | 152 | 0 | |||
Successful Treatment of Saksenaea sp. Osteomyelitis by Conservative Surgery and Intradiaphyseal Incorporation of Amphotericin B Cement Beads | Antimicrobial Agents and Chemotherapy | 2019 | 162 | 0 | |||
Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria | Haematologica | 2019 | 222 | 133 | |||
Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome | Bone Marrow Transplantation | 2018 | 384 | 0 | |||
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia | Haematologica | 2017 | 169 | 74 | |||
Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia | Leukemia and Lymphoma | 2016 | 112 | 0 | |||
Posttraumatic mucormycosis: a nationwide study in France and review of the literature | Medicine (Baltimore) | 2014 | 125 | 0 | |||
Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution | Leukemia Research | 2014 | 143 | 0 | |||
Dynamics of cytomegalovirus populations harbouring mutations in genes UL54 and UL97 in a haematopoietic stem cell transplant recipient | Journal of Clinical Virology | 2013 | 113 | 0 |